JPMorgan lowered the firm’s price target on Novo Nordisk (NVO) to DKK 500 from DKK 650 and keeps an Overweight rating on the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVO:
- Eli Lilly Stock (LLY) Will Benefit from ‘Onshoring Boom,’ Says BMO Capital Markets
- Notable open interest changes for July 30th
- Novo Nordisk downgraded to Neutral from Buy at BofA
- Novo Nordisk downgraded to Neutral from Outperform at Oddo BHF
- Citi opens ‘upside catalyst watch’ on Eli Lilly post selloff